ALNY vs. BMRN: Alnylam Pharmaceuticals vs. BioMarin Pharmaceutical Stock Comparison
How do Alnylam Pharmaceuticals (ALNY) and BioMarin Pharmaceutical (BMRN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Alnylam Pharmaceuticals (ALNY) and BioMarin Pharmaceutical (BMRN) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | ALNY | BMRN |
|---|---|---|
| Name | Alnylam Pharmaceuticals, Inc. | BioMarin Pharmaceutical Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 20.89 billion USD | 10.85 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 1, 2004 | July 26, 1999 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ALNY | BMRN |
|---|---|---|
| Total Return (1Y) | -64.57% | 8.82% |
| Total Return (3Y, Annualized) | -1.58% | -12.54% |
| Total Return (5Y, Annualized) | -3.13% | -7.51% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ALNY | BMRN |
|---|---|---|
| Volatility (1Y, Annualized) | 54.08% | 35.50% |
| Beta (5Y) | 0.45 | 0.24 |
| Max Drawdown (5Y) | -68.25% | -57.64% |
| Avg. Volume (3M) | 1.90M | 2.28M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ALNY | BMRN |
|---|---|---|
| Sharpe Ratio (1Y) | -1.27 | 0.13 |
| Sortino Ratio (1Y) | -1.45 | 0.23 |
Profitability
ROE (TTM)
BioMarin Pharmaceutical (BMRN) reports a negative ROE of -0.31%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Alnylam Pharmaceuticals (ALNY) reports 138.07%, ranking against industry peers normally.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
138.07%
- ALNY
- 138.07%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.31%
- Max
- 109.18%
- Q3
- 6.23%
- BMRN
- -0.31%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile Alnylam Pharmaceuticals (ALNY) reports 52.85%, ranking against industry peers normally.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.85%
- ALNY
- 52.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.52%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- BMRN
- -0.52%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Alnylam Pharmaceuticals (ALNY) at 23.72% and BioMarin Pharmaceutical (BMRN) at 26.58% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.72%
- Max
- 83.12%
- ALNY
- 23.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.58%
- Max
- 83.12%
- BMRN
- 26.58%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ALNY | BMRN |
|---|---|---|
| ROE (TTM) | 138.07% | -0.31% |
| ROA (TTM) | 9.51% | 3.89% |
| Net Margin (TTM) | 52.85% | -0.52% |
| Operating Margin (TTM) | 23.72% | 26.58% |
| Gross Margin (TTM) | 77.28% | 53.21% |
Growth
Revenue Growth
Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while BioMarin Pharmaceutical (BMRN) at 12.87% is closer to the peer norm — faster top-line expansion for ALNY.
EPS Growth
Only one side can be read here: BioMarin Pharmaceutical (BMRN) reports EPS growth of -18.55%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.
Growth Metrics
| Metric | ALNY | BMRN |
|---|---|---|
| Revenue Growth (YoY) | 65.19% | 12.87% |
| Revenue Growth (3Y CAGR) | 52.98% | 15.40% |
| EPS Growth (YoY) | -- | -18.55% |
| EPS Growth (3Y CAGR) | -- | 33.89% |
Financial Strength
Current Ratio (MRQ)
Alnylam Pharmaceuticals (ALNY) at 2.48 keeps current ratio within its industry’s typical mid-range, while BioMarin Pharmaceutical (BMRN) at 2.44 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BMRN.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.48
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ALNY
- 2.48
- Q1
- 2.47
- Min
- 0.10
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.44
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BMRN
- 2.44
- Min
- 0.10
Debt / Equity (MRQ)
Both Alnylam Pharmaceuticals (ALNY) at 0.83 and BioMarin Pharmaceutical (BMRN) at 0.67 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 1.42
- ALNY
- 0.83
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67
- Max
- 1.42
- BMRN
- 0.67
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ALNY | BMRN |
|---|---|---|
| Current Ratio (MRQ) | 2.48 | 2.44 |
| Debt / Equity (MRQ) | 0.83 | 0.67 |
| Net Debt / EBITDA | -0.57 | 4.04 |
Dividends
Dividend Yield (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor BioMarin Pharmaceutical (BMRN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor BioMarin Pharmaceutical (BMRN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ALNY | BMRN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Alnylam Pharmaceuticals (ALNY) trades at 7.88 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.88
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- ALNY
- 7.88
- Min
- 0.07
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BMRN
- --
P/S Ratio (TTM)
BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while Alnylam Pharmaceuticals (ALNY) at 4.17 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.17
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ALNY
- 4.17
- Q1
- 3.01
- Min
- 0.01
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.97
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- BMRN
- 2.97
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Alnylam Pharmaceuticals (ALNY) at 5.79 and BioMarin Pharmaceutical (BMRN) at 1.73 are valued close to their industries’ norm against book — neither stands out from peers.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.79
- Max
- 13.53
- Q3
- 6.54
- ALNY
- 5.79
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BMRN
- 1.73
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ALNY | BMRN |
|---|---|---|
| P/E Ratio (TTM) | 7.88 | -- |
| P/S Ratio (TTM) | 4.17 | 2.97 |
| P/B Ratio (MRQ) | 5.79 | 1.73 |
| Free Cash Flow Yield (TTM) | 1.57% | -0.15% |